The firm said the capacity expansion is necessary as it has become increasingly successful in the sports, food and health sectors, primarily with its versatile Creapure and Creavitalis products.
The €120m investment will be ploughed into the construction of an increasingly automated production plant for creatine and its precursors—the building blocks the body uses to make creatine, such as sodium sarcosinate and cyanamide— thereby ensuring the entire creatine value chain.
Alzchem expects the investment to generate additional annual sales in the low hundreds of millions, along with a strong boost to earnings.
Commissioning is planned in stages, starting in the second half of 2027.
“As the only producer outside Asia, we are participating to a significant extent in the continuing growth in market demand for high-purity creatine,” said Andreas Niedermaier, CEO of Alzchem Group AG. “We benefit above all from our strong position in the premium segment: We are the quality ‘Made in Germany’ leader in the sports market with Creapure and in the health market with Creavitalis.
“We also see attractive long-term growth potential in new areas of application, which we intend to consistently exploit with our broad product portfolio, for example in women’s health and healthy aging.”
Although the firm would not disclose how the investment would impact ingredient prices, Andrea Lochner, corporate communications and investor relations lead at Alzchem, told NI the work would “strengthen its competitive position in the premium segment”.
Growth outlook
Creatine has been highlighted as a key trend to watch within the supplements sector in 2026 and beyond, thanks to its significant scientific portfolio and wealth of health benefits. It has even been argued the compound should be considered a semi-essential nutrient.
“Creatine has gained significant popularity in recent years, evolving from a pure sports nutrition ingredient to a key component in health and nutrition. Global demand for creatine has risen sharply, with premium segments such as Creapure growing above average," Lochner told NI. “Drivers include scientific evidence, EU-approved health claims, and new product formats that make creatine suitable for everyday use.”
Lochner noted key factors driving the growth include, “the increase in women taking creatine both for sports and for female health, the destigmatization of creatine overall, and numerous studies demonstrating benefits beyond sports further accelerate adoption, alongside partnerships with leading brands such as our collaboration on high-protein products.
Innovation opportunities
The firm highlighted its partnership with Ehrmann as an example of Creapure’s expanding applications.
In October 2025, Ehrmann launched an expansion of its High Protein Creatine product line, with its Ehrmann High Protein Creatine.
Niedermaier said this makes “creatine available to a broad target group for the first time in the form of everyday food products in the three categories of puddings, drinks and bars”.
“Alzchem ensures that this enrichment of the long-established Ehrmann protein products is reliably carried out with the highest quality creatine,” he added.
Prominent nutrition influencer James Smith recently launched his own creatine supplement highlighting the use of Creapure as the product’s USP, touting the ingredient as the most trustworthy for dosage and bioavailabilty. The product’s marketing focuses on Creapure’s cognitive health benefits.
Lochner added: “Creapure stands for premium creatine monohydrate, purity, and safety, and is the global standard for sports nutrition. The areas of women’s health, cognitive performance, healthy aging, and longevity — in short, overall health — represent an extremely exciting and forward-looking field for Creavitalis."
